U
Overview
USDTL provides toxicology testing and drug screening using hair, nail, and umbilical cord specimens for healthcare providers, legal entities, and research institutions, offering standard and customized panels. Clients submit samples, USDTL runs panel-based analyses, and reports results with interpretations, emphasizing fast turnaround times. The company differentiates itself by using specimen types beyond blood or urine and by offering customized panels with quick, reliable results. Its goal is to be a leading provider of precise, fast, and reliable drug-screening services that detect illicit substances across multiple specimen types.
Work here?Claim your company
Simplify's take
What believers are saying
- January 2025 Northlane backing funds acquisitions, automation, and sales expansion.
- 2025-2026 panels added ketamine, xylazine, gabapentin, and tianeptine detection.
- CourtFact integration should lift referrals from courts, probation, and treatment networks.
What critics are saying
- Northlane ownership can force growth targets before laboratory operations fully scale.
- USDTL's January 2026 clinical expansion invites MedTox, Labcorp, and Quest retaliation.
- SAMHSA certification changes or quality failures would cripple federal testing revenue quickly.
What makes United States Drug Testing unique
- USDTL owns niche hair, nail, and umbilical-cord toxicology workflows.
- January 2026 CourtFact integration embeds USDTL inside justice-program case management.
- January 2026 clinical-specimen launch broadens USDTL beyond forensic-only testing.
Help us improve and share your feedback! Did you find this helpful?